DJIA 17,814.94 -2.96 -0.02%
NASDAQ 4,758.25 3.36 0.07%
S&P 500 2,067.03 -2.38 -0.12%
market minute promo

CLOVIS ONCOLOGY INC (NASDAQ: CLVS)

47.45 -0.83 (-1.72%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CLVS $47.45 -1.72%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $48.28
Previous Close $48.28
Daily Range $47.08 - $48.31
52-Week Range $35.33 - $93.33
Market Cap $1.6B
P/E Ratio -11.92
Dividend (Yield) $0.00 (0.0%)
Volume 806,120
Average Daily Volume 842,464
Current FY EPS -$4.47

Sector

Industry

CLOVIS ONCOLOGY INC (CLVS) Description

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets. Website: http://www.clovisoncology.com/

News & Commentary

3 Beaten Down Biotech Stocks to Buy Now

The share prices of Dynavax Technologies, CellDex Therapeutics, and Clovis Oncology have all plunged this year. Here is why I think these beaten down biotechs are now compelling buys.

CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucap

CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data

Morning Market Losers

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly

Clovis Oncology Enters Into Oncology Clinical Trial Collaboration With GlaxoSmithKline

Clovis Oncology (CLVS) Shares Cross Below 200 DMA

Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare Conference (Transcript)

UPDATE: Stifel Reiterates On Clovis Oncology Following 3Q14 LPS

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript

Super Important Biotech and Drug Stock Events for November

AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog

See More CLVS News...